Mexico approves emergency use of Lilly's COVID-19 treatment




  • In US
  • 2021-12-01 17:36:24Z
  • By Reuters
 

MEXICO CITY (Reuters) - Mexico's health regulator Cofepris said on Wednesday it had approved U.S. pharmaceutical firm Eli Lilly and Co's antibody treatment against COVID-19 for emergency use with infected patients at risk from comorbidities.

Cofepris said in a statement it had granted the emergency use of Lilly's injectable combination of bamlanivimab and etesevimab to treat mild to moderate cases of coronavirus in people above the age of 12 who weigh at least 40 kilograms.

The U.S. Food and Drug Administration had previously approved emergency use of the combination.

Cofepris noted that the Lily antibody treatment does not replace licensed COVID-19 vaccines.

(Reporting by Raul Cortes; Editing by Chizu Nomiyama)

COMMENTS

More Related News

DeSantis fumes over FDA interference on monoclonal antibody treatments
DeSantis fumes over FDA interference on monoclonal antibody treatments

Gov. Ron DeSantis is blasting the Biden administration after the FDA revoked the use of two different monoclonal antibody treatments, forcing Florida to...

Suspension Of Antibody Treatments
Suspension Of Antibody Treatments 'Reckless,' Says FL Governor

DeSantis said the decision to revoke approval of the COVID-19 antibody treatments "was based on the whims of a floundering president."

Georgia bill would ban abortion pills by mail, require exams
Georgia bill would ban abortion pills by mail, require exams

Republicans in Georgia have introduced a bill that bans the delivery of abortion pills by mail. It would require anyone who wants to use abortion pills to...

Florida monoclonal antibody sites shut down after FDA decision. What happens now?
Florida monoclonal antibody sites shut down after FDA decision. What happens now?

Florida monoclonal antibody sites have closed following the U.S. Food and Drug Administration's announcement that Regeneron and Eli Lilly's treatments shouldn't be used because they don't work against the COVID omicron variant.

U.S. FDA to restrict use of Regeneron, Lilly COVID antibody drugs - WaPo
U.S. FDA to restrict use of Regeneron, Lilly COVID antibody drugs - WaPo

The U.S. Food and Drug Administration (FDA) is likely to restrict the use of COVID-19 antibody treatments from Regeneron and Eli Lilly as they are...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US